Should Academic Emergency Departments Collaborate in Pharmaceutical Industry-Sponsored Research?: The Dangers of Industry-Funded Research in Emergency Medicine by Stone, Susan & Herbert, Mel
Page  61 The California Journal of Emergency Medicine IV:1,Jul-Oct 2003
Our second installment of CaJEM Pro/Con exam-
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Historically, academic centers have been the venue
for conducting important clinical trials.  Teams of well-
trained investigators functioning in well controlled
settings have set the standard for rigorous scientific
design and data interpretation in clinical trials.
Institutional review boards have contributed to
research subject safety and minimization of scientific
misconduct.  This system has been in place throughout
time and we have seen many amazing discoveries.
However, with rising medical costs and greater
economic restraints, the academic centers have lost
funding and turned to private sources of investment.
The once clear boundary between industry and
academic centers is now frighteningly blurred; even
worse, many drug trials are conducted entirely outside
traditional academic centers.  The pharmaceutical
industry now runs much of the medical research in
this country, but the questions is:  To to whom are
these companies and academics now accountable?1
While academic centers have felt this tightening with
budgetary constraints, the pharmaceutical industry
continues to flourish. In 2000, $2.5 billion were spent
on direct advertising to consumers.  Increases in the
sales of the 50 drugs most heavily advertised to
consumers were responsible for almost half (47.8%)
of the $20.8 billion increase in pharmaceutical
spending in 2000. Despite strong revenues, the
“research-based” pharmaceutical industry spends
more on marketing and administration than it does on
research and development (R&D).  Since 1995, R&D
staff of U.S. brand name drug companies have
decreased by 2%, while marketing staff have
increased by 59%.  Currently, 22% of staff are
employed in research and development, while 39%
are in marketing. 2
When looking at pharmaceutical sponsored trials, we
must ask, “What is the motive?”  The primary role of
industry is to make money and the secondary goal is
to promote public health.  History has shown that when
these two clash, the monetary motive may win.1 1
When clinical trials are successful, widespread support
is achieved by publication in medical journals.  This
results in financial gains for industry and it may
contribute to our patients’ health.   However, some of
this research leads to biased reporting.  This is
demonstrated by the increasing number of clinicians
performing research for a specific pharmaceutical
company and then becoming the “experts”.   These
experts travel the country and speak at a variety of
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same experts write most the reviews on the drugs
they have researched.  These activities can be quite
lucrative for the academics involved, many of whom
earn far less in their clinical practice than their private
practice colleagues.  Whether they want to or not,
these experts become part of the pharmaceutical
marketing machine, rather than part of the traditional
unbiased academic review team.
Aside from the questionable credentials of what
constitutes being labeled as an “expert”, the results
and presentation of industry sponsored research may
be dubious.  The vast majority of the trials performed
by industry have “positive” results. 3  The spin put on
the trial results is also equally positive.  In many cases
it is difficult to determine where the expert ends and
the marketing department begins. 4,5
What is clear is that drug development is expensive.
It is estimated that the average cost of bringing a new
drug to market in the United States is about $500
million.  Multicenter trials are usually required to enter
adequate numbers of patients.  How do
pharmaceutical companies manage these costs?
Contract research organizations (CROs) are private
consultant companies that organize these trials for
financial gain.  They are a clear winner over academic
centers as they can set up trials for less money and
allow speedier collection of data.  For example, in
2000 in the United States, CROs received 60% of
the research grants from pharmaceutical companies,
as compared with only 40% received by academic
centers.
Another less obvious advantage to using the CRO is
that terms are set by the industry regarding
methodology, which may not always be in the best
interest of patients or  of gaining an understanding of
the disease in question.  Additionally, part of
participation in working as an investigator is that there
is typically no access to the raw data, and limited
participation in data interpretation5.
As more drugs are developed and prices continue to
escalate, we will continue to see more physician
profiling and industry sponsored research.  Ideally,
we would be immune to the affects of “detailing” by
pharmaceutical representatives.   Critical appraisal of
the literature would keep us honest and medicine would
be practiced based on best evidence.  However the
pharmaceutical industry’s infiltration into daily practice
is evidenced by physician behavior on a daily basis.
Sigworth et al, in a study published in 2001, looked
at the effect of pharmaceutical industry gifts on
physician practice6. Residents completed a
questionnaire, after which all of the items they carried
in their white coats were inspected to identify
pharmaceutical company brand names or logos.
Nearly all of the residents had eaten an
industrysponsored meal within the previous year
(98%), believed that industry representatives had
accurately presented their products (99%), and felt
that these activities at least partially influenced their
prescribing habits (91%).  It is interesting that only
13% stated that they would be willing to wear a
product advertisement patch on their white coats, like
a NASCAR® driver.  Yet nearly all of them (97%)
were carrying at least one item having a pharmaceutical
insignia, and about half of all items carried were
branded (a median of four items per resident).  The
branded items most commonly carried included
reference books (carried by 90%), calipers (85%),
pens (79%) and information cards (70%).  Most of
these residents seemed to be aware of the influence
of pharmaceutical representatives, but most also
carried branded items.Page  63 The California Journal of Emergency Medicine IV:1,Jul-Oct 2003
The same marketing occurs on a medical school level.
In an editorial in May of 2000, in the New England
Journal of Medicine 6, the author laments the decisions
of major universities in the past few years to further
strengthen their ties to the pharmaceutical industry.
The question is asked: “What is the justification for
this large scale breaching of the boundaries between
academic medicine and for-profit industry?”  The
answer is money.  The secondary effects of improved
communication between industry and academic
centers is clearly a secondary gain at best.
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I greatly enjoyed reading Dr. Stone’s and Dr.
Herbert’s composition on pharmaceutical company
sponsored research.  While clinical trials conducted
in academic medical centers were not immune to some
of the problems of conflict of interest, it is a shame
that so many of the important drug trials and so much
funding for research is currently going to other, typically
for profit, research corporations.  Drs. Stone and
Herbert also correctly note that marketing budgets
have increased by as much as 50% compared to
research and development research and development
(R&D) budgets recently.  Since the restrictions were
relieved, pharmaceutical companies found that direct
to consumer marketing is far more effective than
physician marketing.  In a sense, it is because of the
paranoia that some physicians display toward any
interaction with drug companies that the industry
turned to direct marketing and discovered it was far
more successful.  Many physicians have driven
pharmaceutical representatives away in a misguided
attempt to prevent undue influence.  Instead of
working hard to convince physicians of the benefits
of using certain medications, now drug companies
simply have to convince a consumer that they want
the drug that will allow them to run across a grassy
field without being crippled by allergy symptoms!
There is an old adage that suggests keeping your friends
close, but your enemies closer.  For those physicians
who see pharmaceutical companies as the enemy,
instead of driving them away from academic medicine,
we should have kept them close and learned to interact